AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
Alameda, Calif.-based Exelixis inked a collaboration, option and license deal with India’s Aurigene Discovery Technologies Ltd., which focuses on oncology and inflammatory diseases.
In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.
GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.
The BIO International Convention is being held in Philadelphia from June 3-6, 2019, with more than 16,000 attendees expected from around the world. The convention draws a list of who’s who in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy, with more than 7,000 companies and 47,000 partnering meetings.
Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.
Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.